Who is sponsoring NCT00406861?

NCT00406861 is sponsored by The Leprosy Mission Bangladesh.

What condition does NCT00406861 study?

NCT00406861 studies Erythema Nodosum Leprosum, Leprosy.

What drugs are being tested in NCT00406861?

Interventions: montelukast in treatment of ENL reaction.

What is the status of NCT00406861?

NCT00406861 is currently UNKNOWN.

Last reviewed 2006-12-01 · How we verify

Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy

NCT00406861 NA UNKNOWN

Objective of the trial is to assess the safety and efficacy of Montelukast in treatment of Erythema Nodosum leprosum (ENL) reaction in multibacillary leprosy patients either in combination with prednisolone or alone. Hypothesis is that montelukast will reduce the severity of ENL reaction in Multibacillary leprosy patients without causing an unacceptably high incidence of adverse effects. Design is a multicentre hospital-based single-blind prospective trial for leprosy patients with ENL reaction. prior written consent will be taken from the patients who will undergo the trial. Endpoints are decrease in severity of ENL and absence of new nerve function impairment

Details

Lead sponsor	The Leprosy Mission Bangladesh
Phase	NA
Status	UNKNOWN
Enrolment	60
Start date	2006-12
Completion	2009-06

Conditions

Erythema Nodosum Leprosum
Leprosy

Interventions

montelukast in treatment of ENL reaction

Primary outcomes

decrease in ENL score
absence of new nerve function impairment
incidence of adverse effects

Countries

Bangladesh